Mark Roskey

Company: Quanterix

Job title: Chief Scientific & Collaboration Officer

Seminars:

Unlocking the Power of Blood-Based Biomarkers in ALS: From Discovery to Clinical Impact 8:30 am

Explore how Simoa® technology is enabling ultra-sensitive detection of biomarkers like  Neurofilament light chain (NfL) to monitor ALS progression and treatment response Gain real-world insights into how NfL is being used in clinical trials to support patient stratification, therapeutic monitoring, and trial design Understand the future of personalized ALS care through the integration of fluid biomarkers into…Read more

day: Conference Day One